In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on ContraFect (CFRX – Research Report),
Tag: Jason McCarthy
Analysts Offer Insights on Healthcare Companies: Immutep (NASDAQ: IMMP) and Sintx Technologies (NASDAQ: SINT)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Immutep (IMMP – Research Report)
ADMA Biologics (ADMA) Gets a Buy Rating from Maxim Group
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on ADMA Biologics (ADMA – Research
Maxim Group Remains a Buy on SCYNEXIS (SCYX)
Maxim Group analyst Jason McCarthy maintained a Buy rating on SCYNEXIS (SCYX – Research Report) yesterday and set a price
SELLAS Life Sciences Group (SLS) Gets a Buy Rating from Maxim Group
Maxim Group analyst Jason McCarthy reiterated a Buy rating on SELLAS Life Sciences Group (SLS – Research Report) yesterday and
Xenetic Biosciences (XBIO) Initiated with a Buy at Maxim Group
Xenetic Biosciences (XBIO – Research Report) received a Buy rating and a $2.50 price target from Maxim Group analyst Jason
Achieve Life Sciences (ACHV) Gets a Buy Rating from Maxim Group
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Achieve Life Sciences (ACHV –